Aethlon agrees to North Immunology merger backed by $180 million financing
Aethlon ($AEMD) Medical agreed to an all-stock merger with North Immunology, accompanied by a private placement described as approximately $180 million in gross proceeds. That amount includes the conversion of roughly $34 million of existing North Immunology notes, so it is not entirely new cash. The combined business expects the financing to support operations into the second half of 2028. The lead program, NOR-101, is an experimental antibody targeting IL-13 and IL-18 for atopic dermatitis and
0